Across TCGA pan-cancer cohorts, CST5 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CST5 data layer compared with 22 for mass-spec protein.
The strongest signal is observed in kidney chromophobe (KICH), where higher CST5 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CST5 expression acts as an unfavorable survival marker.
KICH and SKCM are the cancer types where CST5 Mutation most reproducibly stratifies survival.